All results
8 results for phase 2 clinical trial patients metastatic neuroblastoma bone
-
Neuroblastoma Maintenance Therapy Trial (NMTT)
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study…
- Ages
- 1 Year - 30 Years
- Sexes
- All
-
PNOC020:RNA-Lipid Particle Vaccines for Newly Diagnosed Ped HGG and Adult GBM
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in…
- Ages
- 21 Years - N/A
- Sexes
- All
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA)…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Genomic-Risk Stratified Txs for Unfavorable Intermediate Risk Prostate Cancer (Guidance)
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…
- Ages
- 18 Years - N/A
- Sexes
- Male
-
DOTS (20-0002)
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
High Risk Prostate CA: Less Intense Tx for Low Risk Scores and More Intense Tx for High Risk Scores
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high…
- Ages
- 18 Years - N/A
- Sexes
- Male